CompletedPhase 1NCT00276536
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Studying Melanoma of soft tissue
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Cleveland Clinic
- Principal Investigator
- Ernest C. Borden, MDThe Cleveland Clinic
- Intervention
- recombinant interferon alpha-1b(biological)
- Enrollment
- 35 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2001 – 2004
Study locations (1)
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00276536 on ClinicalTrials.govOther trials for Melanoma of soft tissue
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06942143An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid TumorsGuangzhou FineImmune Biotechnology Co., LTD.
- RECRUITINGPHASE1NCT06889766NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and SarcomaCentre Hospitalier Universitaire Vaudois
- ACTIVE NOT RECRUITINGNANCT05121545Proton Pencil Beam Scanning GRID for Treatment of Bulky TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05231655Ex VIvo DEtermiNed Cancer TherapySheffield Teaching Hospitals NHS Foundation Trust